Shares in Thousand Oaks-based biotech company Amgen Inc. closed up more than 12 percent Monday after the company reported profit that exceeded Wall Street’s expectations.

During the second quarter, the company earned $941 million (87 cents per share), a 7.6 percent decline from $1.02 billion (90 cents) in the same period a year earlier. Excluding ongoing restructuring charges and acquisition costs, profit rose to $1.14 per share, which topped analysts’ expectations of $1.02 per share.

Sales for Amgen rose just under 1 percent to $3.76 billion also beating analysts’ predictions of $3.58 billion.

For the full fiscal year, the company now expects profit between $4.25 and $4.45 per share, excluding charges, up from a $4 to $4.30 per share estimate made earlier this year. Sales are expected to range from $14.6 billion to $14.9 billion, up from prior guidance of $14.2 to $14.6 billion.

Shares in Amgen reached their highest point in more than a year after the earnings report was released and after a morning announcement that its osteoporosis drug, denosumab, is expected to be submitted for approval by the FDA around the beginning of next year.

Shares in Amgen closed Monday at $60.48.